A Simple Test to Identify the Risk of NASH and Cirrhosis in People with Obesity or Diabetes: The Time to Screen Is Now

被引：2
作者：
Cusi, Kenneth [1 ]
机构：
[1] Univ Florida, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd,Rm H-2, Gainesville, FL 32610 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2022年 / 107卷 / 07期
关键词：
nonalcoholic fatty liver disease; NASH; type; 2; diabetes; obesity; hepatic steatosis; insulin resistance; FIB-4; NFS; PRO-C3; CK-18; MANAGEMENT;
D O I：
10.1210/clinem/dgac186
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E3076 / E3077
页数：2
相关论文
共 8 条
  • [1] Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
    Barb, Diana
    Repetto, Enrico M.
    Stokes, Michael E.
    Shankar, Sudha S.
    Cusi, Kenneth
    [J]. OBESITY, 2021, 29 (11) : 1950 - 1960
  • [2] EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update
    Berzigotti, Annalisa
    Tsochatzis, Emmanouil
    Boursier, Jerome
    Castera, Laurent
    Cazzagon, Nora
    Friedrich-Rust, Mireen
    Petta, Salvatore
    Thiele, Maja
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 (03) : 659 - 689
  • [3] Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
    Bril, Fernando
    McPhaul, Michael J.
    Caulfield, Michael P.
    Clark, Virginia C.
    Soldevilla-Pico, Consuelo
    Firpi-Morell, Roberto J.
    Lai, Jinping
    Shiffman, Dov
    Rowland, Charles M.
    Cusi, Kenneth
    [J]. DIABETES CARE, 2020, 43 (02) : 290 - 297
  • [4] Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
    Bril, Fernando
    Leeming, Diana Julie
    Karsdal, Morten Asser
    Kalavalapalli, Srilaxmi
    Barb, Diana
    Lai, Jinping
    Rabe, Matthew
    Cusi, Kenneth
    [J]. DIABETES CARE, 2019, 42 (07) : 1348 - 1351
  • [5] Chalasani NP, 2017, HEPATOLOGY, V66, p303A
  • [6] Cusi K., 2022, ENDOCR PRACT
  • [7] Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
    Kanwal, Fasiha
    Shubrook, Jay H.
    Adams, Leon A.
    Pfotenhauer, Kim
    Wong, Vincent Wai-Sun
    Wright, Eugene
    Abdelmalek, Manal F.
    Harrison, Stephen A.
    Loomba, Rohit
    Mantzoros, Christos S.
    Bugianesi, Elisabetta
    Eckel, Robert H.
    Kaplan, Lee M.
    El-Serag, Hashem B.
    Cusi, Kenneth
    [J]. GASTROENTEROLOGY, 2021, 161 (05) : 1657 - 1669
  • [8] Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
    Qadri, Sami
    Ahlholm, Noora
    Lonsmann, Ida
    Pellegrini, Paola
    Poikola, Anni
    Luukkonen, Panu K.
    Porthan, Kimmo
    Juuti, Anne
    Sammalkorpi, Henna
    Penttila, Anne K.
    D'Ambrosio, Roberta
    Soardo, Giorgio
    Leeming, Diana J.
    Karsdal, Morten
    Arola, Johanna
    Kechagias, Stergios
    Pelusi, Serena
    Ekstedt, Mattias
    Valenti, Luca
    Hagstrom, Hannes
    Yki-Jarvinen, Hannele
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (05) : E2008 - E2020
1